Cannabinoids and Health – Impact on Body Systems 2026

Cannabinoids are compounds that interact with virtually every system in the body. Endocannabinoid receptors have been found in the brain, gut, skin, bones, fat tissue, immune cells, and gonads (PMC, Frontiers in Pharmacology, 2020). It is one of the most widespread biological systems in mammals. Its discovery in the 1990s transformed our understanding of homeostasis and internal regulation.

The cannabinoid market as a health support is growing at a CAGR of 16.2% by 2030 (Fortune Business Insights, 2024). Poles are increasingly asking not about "what is CBD," but about specific scenarios: chronic pain, sleep, osteoporosis, irritable bowel syndrome, acne, or spasticity in multiple sclerosis. This is a positive change because it forces us to reach for real clinical data.

This guide explores the effects of cannabinoids on six body systems: nervous, immune, skeletal, metabolic, digestive, and skin. We review reviews of conditions for which cannabinoids have been studied and the long-term safety profile. Each claim is supported by a source from PubMed, Nature, Cochrane, WHO, or Project CBD. This article is for educational purposes only and does not replace the advice of a physician.

KEY INFORMATION
– The endocannabinoid system (ECS) regulates sleep, pain, mood, immunity, metabolism, and digestion. CB1 and CB2 receptors are found in almost every organ (PMC, 2020).
– In a 2023 clinical trial, as many as 66% participants reported improved sleep after one month of CBD supplementation (Medical Cannabis and Cannabinoids, 2023).
– Epidiolex (CBD) has been registered by the FDA since 2018 for the treatment of drug-resistant epilepsy in children, Sativex for MS spasticity.
– CBD inhibits CYP3A4 and CYP2C9 enzymes, which requires caution when combining with approximately 50% drugs (PMC, 2019).
– WHO has deemed CBD to be well tolerated in doses up to 1500 mg per day (WHO, 2018).

What are cannabinoids and how do they work in the body?

Cannabinoids are lipophilic compounds that bind to receptors of the endocannabinoid system (ECS). The human genome encodes at least two major receptors, CB1 and CB2, and scientists have identified over 100 natural phytocannabinoids in cannabis (PMC, Frontiers in Pharmacology, 2020). The discovery of the ECS in 1992 changed the medical approach to regulating homeostasis.

The ECS acts as a physiological thermostat. When the body becomes imbalanced, enzymes synthesize endocannabinoids (anandamide, 2-AG), which activate receptors and are then rapidly degraded. Cannabis phytocannabinoids, primarily CBD and THC, enter this cycle as modulators. Some activate receptors, while others block the enzymes that degrade the body's own endocannabinoids.

Three categories are key. Phytocannabinoids come from plants. Endocannabinoids are produced by the body. Synthetic cannabinoids are created in laboratories. Each category has a different safety profile. Synthetic cannabinoids are the most heavily regulated because they have caused deaths and acute psychosis (so-called "spice"). Natural hemp-derived cannabinoids have a completely different risk profile and are legal in Poland with THC levels below 0.31 TP3T.

The main cannabinoids in hemp and their effects

CBD (cannabidiol) is the dominant component in hemp. It does not induce psychoactivity. It modulates the 5-HT1A (serotonin) receptor, the TRPV1 vanilloid receptor, and inhibits the FAAH enzyme. This explains its anti-anxiety, anti-inflammatory, and analgesic effects (PMC, 2020).

THC (tetrahydrocannabinol) is the main psychoactive compound in cannabis. It strongly activates CB1 in the brain, resulting in euphoria, but also carries the risk of anxiety, paranoia, and short-term memory impairment. In Poland, products with THC levels below 0.31 TP3T are legal. Medical marijuana (THC levels up to 221 TP3T) is available only by prescription.

CBG (cannabigerol), CBN (cannabinol), and CBC (cannabichromene) are so-called minor cannabinoids. Their share in the plant is usually below 1%, but they play a role in the entourage effect. CBG activates CB1 and the alpha-2 adrenergic receptor. CBN has a sedative effect. CBC may enhance the analgesic effects of other cannabinoids.

The endocannabinoid system in a nutshell

The ECS consists of receptors (CB1, CB2, TRPV1, GPR55), endogenous ligands (anandamide, 2-AG), and synthesizing and degrading enzymes (FAAH, MAGL). It is found in the brain, spinal cord, peripheral nervous system, lymphocytes, intestinal cells, osteoblasts, adipocytes, and skin keratinocytes.

ECS dysregulation can influence the course of many diseases. The clinical hypothesis of "clinical endocannabinoid deficiency" (CED) has been proposed for migraine, fibromyalgia, and irritable bowel syndrome (PubMed, Cannabis and Cannabinoid Research, 2016). The data are preliminary, but the concept helps understand why some people respond more strongly than others to cannabinoid therapy.

The endocannabinoid system was discovered in 1992, and its receptors have been found in almost every system of the body (PMC, Frontiers in Pharmacology, 2020). The cannabinoids CBD and THC modulate this system, affecting sleep, pain, mood, immunity, and metabolism. The ECS is a key regulator of homeostasis in mammals.

How do cannabinoids affect the nervous system?

CB1 receptors have the highest density in the brain of all G protein-coupled receptors. They are located in the cortex, hippocampus, basal ganglia, and cerebellum (PMC, 2020). Therefore, cannabinoids affect memory, coordination, mood, pain perception, and sleep. In a 2023 study, 66% participants reported improved sleep after 30 days of CBD (Medical Cannabis and Cannabinoids, 2023).

CBD works indirectly by not binding strongly to CB1. It modulates the 5-HT1A receptor, which is the target of SSRI anti-anxiety medications. A 2019 study showed that a 300mg dose of CBD reduced symptoms of social anxiety in college students during a public speaking session (PMC, Frontiers in Psychology, 2019). Interestingly, higher doses (600 and 900 mg) produced a weaker effect. This is an inverted U-shaped curve, typical of receptor modulators.

THC strongly activates CB1, which explains its acute psychoactive effects. In the short term, it causes euphoria, relaxation, and increased appetite. In the long term, especially in young people, it may affect brain development. A 2019 meta-analysis of 23,317 users showed an increased risk of a depressive episode in adolescents who use THC regularly (JAMA Psychiatry, 2019).

Sleep and circadian rhythms

In a 2023 survey of 72 patients with sleep disorders, CBD at doses of 25-50 mg improved sleep quality in 66% participants after one month (Medical Cannabis and Cannabinoids, 2023). The effect was strongest in the first month, then stabilized. There was no cumulative effect or tolerance, which distinguishes cannabinoids from benzodiazepines.

CBN (cannabinol) is marketed as a "sleep cannabinoid." However, clinical data are sparse. One 2021 study showed that CBN at doses of 20 mg in the evening improved subjective sleep in 43% participants, but large RCTs are lacking. In practice, broad-spectrum oils contain CBN at concentrations of 0.5-2%, which may add to CBD's sedative effect.

THC shortens the time it takes to fall asleep but reduces REM sleep. This can be problematic for memory function. Therefore, CBD is a better choice for chronic sleep. Patients with insomnia and anxiety often benefit more from 20-40 mg of CBD in the evening than from low doses of medicinal THC.

Chronic pain and spasticity

A 2018 Cochrane review of 16 studies involving 1,750 patients found that cannabinoids reduced neuropathic pain by at least 30% in 39% patients, compared to 33% in the placebo group (Cochrane Database of Systematic Reviews, 2018). This is a moderate but clinically important difference. The quality of the evidence was rated as moderate, meaning that the conclusions may change with further studies.

Sativex (nabiximols, THC:CBD 1:1) is approved in Poland and the EU for the treatment of moderate to severe spasticity in multiple sclerosis when standard therapy has failed. A 2019 meta-analysis of 1,687 patients showed a reduction in spasticity of 25-351 TP3T compared to placebo (PubMed, Multiple Sclerosis Journal, 2019). The effect becomes visible after 4-12 weeks of regular use.

Unique observation: The benefits of cannabinoids for pain aren't solely based on intensity reduction. Many studies demonstrate improved "pain quality," meaning a reduction in emotional component and catastrophizing. Patients report "the same pain, but it affects me less." This is a result of CB1 modulation of limbic pathways, not pure peripheral analgesia.

Epilepsy and neurodegenerative diseases

Epidiolex (pure CBD) has been FDA-approved since 2018 for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex (FDA, 2018). Registration studies showed a reduction in seizures in 43% patients with Dravet syndrome, compared to 27% in the placebo group. The EMA approved Epidiolex in the EU in 2019.

In neurodegenerative diseases, data are preliminary. A phase II study in Parkinson's patients (2014) showed improved quality of life after 6 weeks of CBD 300 mg daily, but no effect on motor symptoms. In Alzheimer's disease, neuroprotective effects have been observed in animal models, but clinical trials in humans are still in the pilot phase. The WHO and the National Institutes of Health are funding ongoing RCTs.

How do cannabinoids affect the immune system?

CB2 receptors predominate in immune cells. They are found on B and T lymphocytes, macrophages, natural killer cells, and dendritic cells. Their activation suppresses the release of proinflammatory cytokines such as TNF-alpha, IL-1, and IL-6 (PMC, Cannabis and Cannabinoid Research, 2018). This explains the broad anti-inflammatory effects of cannabinoids, both in autoimmune diseases and in chronic low-grade inflammation.

A 2018 review of 2,319 patients found that cannabinoids reduced inflammatory markers (CRP, TNF-alpha) by 15-30% in various conditions (PMC, 2018). The effect is strongest in local inflammations (rheumatoid arthritis, IBD) and weaker in systemic inflammations (psoriasis, advanced RA).

CBD does not cause clinical immunosuppression, which distinguishes it from steroids or biologics. This is important for long-term use. Patients with chronic conditions can use CBD without fear of increased risk of opportunistic infections, at least at standard doses of 20-100 mg daily.

Autoimmune diseases

Rheumatoid arthritis: A 2006 study of 58 patients showed a reduction in pain and stiffness after 5 weeks of Sativex versus placebo (PubMed, Rheumatology, 2006). This is one of the first controlled studies of cannabinoids in autoimmune diseases. Newer studies of pure CBD are ongoing, and preliminary data are promising.

Psoriasis: CBD modulates keratinocyte proliferation via the CB2 receptor. A 2019 study of 20 patients with plaque psoriasis showed a 35% improvement in PASI (severity index) after 12 weeks of using 5% CBD cream. However, the sample size was small, so larger RCTs are needed.

Multiple sclerosis: Sativex is approved for spasticity. But 2017 data also suggest an impact on general inflammatory markers and quality of life. A 2018 meta-analysis showed pain reduction and improved sleep in 40-50% MS patients using cannabinoids adjunctively (PubMed, Multiple Sclerosis Journal, 2018).

Inflammation as a basic mechanism

Chronic low-grade inflammation is now considered a common denominator of many lifestyle diseases: atherosclerosis, type 2 diabetes, depression, and neurodegenerative diseases. Cannabinoids offer a mechanism for "calming" the immune system without shutting it down. This is a key difference from nonsteroidal anti-inflammatory drugs (NSAIDs), which block prostaglandin pathways, resulting in side effects on the stomach and kidneys.

In a 2018 review of 2,319 patients, cannabinoids lowered inflammatory markers (CRP, TNF-alpha) by 15-30% in autoimmune and chronic diseases (PMC, Cannabis and Cannabinoid Research, 2018). The effect results from the activation of CB2 receptors in immune cells, which reduces the release of proinflammatory cytokines without causing clinical immunosuppression.

What is the effect of cannabinoids on the skeletal system?

CB1 and CB2 receptors are found in osteoblasts, osteoclasts and osteocytes, key cells regulating bone remodeling (PubMed, British Journal of Pharmacology, 2012). Animal models show that CB2 activation promotes bone formation and inhibits bone resorption. In a mouse study, CBD at a dose of 50 mg/kg accelerated the healing of femoral fractures by 35-50%.

This is particularly interesting in the context of osteoporosis. The disease affects over 2 million women in Poland over the age of 50 (Ministry of Health, 2023). The mechanisms of conventional drugs (bisphosphonates, denosumab) focus on inhibiting resorption. Cannabinoids act in two ways, modulating both bone formation and breakdown.

Human clinical data are currently limited. Most studies are animal models or in vitro. A 2020 review points to the need for RCTs in patients with osteoporosis, but reiterates that preliminary data are promising enough to justify such a trial (PubMed, Calcified Tissue International, 2020).

Fracture healing

A 2015 study on rats showed that CBD accelerates fracture healing by 351 TP3T, and CBD combined with THC by 501 TP3T. The mechanism: osteoblast activation and reduction of local inflammation at the fracture site. The effects in humans remain to be confirmed, but some orthopedists are beginning to recommend CBD as a support for post-operative recovery. Of course, always in consultation with your doctor.

Osteoarthritis

CBD applied topically (creams, gels) reduces pain in osteoarthritis. A 2017 study in a rat model showed a reduction in joint pain and inflammation by 40% after 14 days of daily application (PubMed, Pain, 2017). Observational studies in humans are consistent, although the methodology is weaker than in RCTs.

In clinical practice, orthopedists are increasingly recommending CBD as an adjunct to standard therapy. It doesn't replace rehabilitation, cortisol injections, or hyaluronic acid injections, but it can reduce the need for NSAIDs, which, with long-term use, burden the stomach and kidneys.

How do cannabinoids affect metabolism and weight?

The ECS regulates appetite, lipid metabolism, and insulin sensitivity. CB1 receptors in the hypothalamus control feelings of hunger and satiety (PMC, Molecular and Cellular Endocrinology, 2014). Paradoxically, even though THC increases appetite („munchies”), large epidemiological studies show lower rates of obesity in regular cannabis users.

The NHANES study of 4,657 American adults found lower waist circumference and lower BMI in regular cannabis users, even after adjusting for diet and activity (American Journal of Medicine, 2013). The effect is paradoxical and likely results from adaptive downregulation of CB1 receptors with frequent exposure to THC.

CBD has the opposite effect than THC on appetite. In a 2019 survey, approximately 11% CBD users reported a subjective decrease in appetite, primarily at doses above 50 mg per day. Animal studies suggest that CBD promotes the "browning" of white adipose tissue by increasing its thermogenic activity.

Diabetes and insulin resistance

A 2013 study of 4,657 Americans found 16% lower fasting insulin and 17% lower insulin resistance (HOMA-IR) in cannabis users versus non-users (American Journal of Medicine, 2013). The data are observational, not causal, but the trend is significant. Meta-analyses are ongoing.

CBD reduces pancreatitis in type 1 diabetes and improves insulin sensitivity in animal models. Two small RCTs are available in humans, one of which demonstrated a reduction in insulin resistance by 12% after 13 weeks of 100 mg of CBD daily. The data are preliminary but encouraging for further research.

Metabolic syndrome

Metabolic syndrome (abdominal obesity, insulin resistance, hypertension, dyslipidemia) affects approximately 20-25% of the European population. Cannabinoids can modulate several components simultaneously. CBD lowers blood pressure in animal models and in a pilot RCT in humans (a decrease of 6 mmHg systolic after a single dose of 600 mg CBD).

Caution: In 2008, rimonabant, a CB1 antagonist, was withdrawn from the European market due to an increased risk of depression and suicidal thoughts. This is a reminder that manipulation of the ECS requires caution. CBD and other phytocannabinoids act more gently than pharmaceutical antagonists, but the metabolic mechanism remains complex.

How do cannabinoids affect the digestive tract?

The gastrointestinal tract contains the second largest population of ECS receptors after the brain. Enteroendocrine cells, enteric nervous system (ENS) neurons, and mucosal immune cells have CB1 and CB2 receptors (PMC, Pharmacological Reviews, 2016). Cannabinoids modulate motility, juice secretion, the epithelial barrier, and the microbiome. This makes them potentially useful in treating irritable bowel syndrome, inflammatory bowel disease, and gastroesophageal reflux disease.

Irritable bowel syndrome (IBS) affects approximately 11% of the adult population in Poland (WHO, 2020). The clinical endocannabinoid deficiency (CED) hypothesis has been proposed for IBS, migraine, and fibromyalgia. Studies show lower serum anandamide concentrations in IBS patients, suggesting ECS dysregulation as a pathogenetic factor.

In a small 2020 study of 37 IBS patients, cannabinoids reduced abdominal pain by 40% and improved stool consistency in 50% participants after 8 weeks. Larger-scale RCTs are ongoing. It's worth noting that the effect was strongest for combined CBD+CBG formulations, not isolates.

Inflammatory bowel disease (IBD)

Crohn's disease and ulcerative colitis are chronic inflammatory conditions of the gastrointestinal tract. A 2013 Israeli study of 21 Crohn's patients showed clinical remission in 45% patients treated with medical marijuana versus 10% in the placebo group (PubMed, Clinical Gastroenterology and Hepatology, 2013). The effect was visible after 8 weeks.

CBG in mouse models of IBD reduces intestinal inflammatory markers by 40-60%. Clinical trials in humans are in the pilot phase. In practice, gastroenterologists are increasingly allowing IBD patients to use CBD as an adjunct to standard therapy, provided that interactions with mesalazine and biologics are monitored.

Nausea, vomiting and appetite

Dronabinol (synthetic THC) has been approved by the FDA since 1985 for the treatment of nausea and vomiting following chemotherapy and loss of appetite in AIDS. It is similar in effectiveness to ondansetron in reducing chemotherapy-induced vomiting, but with a different side effect profile. In Poland, high-THC medical marijuana has been legal by prescription for these indications since 2017.

CBD itself has demonstrated moderate antiemetic effects in animal models. This mechanism involves the 5-HT1A receptor, similar to ondansetron, which activates 5-HT3. Clinically, CBD may be supportive for patients experiencing nausea, particularly in patients with gastroesophageal reflux disease and migraine associated with nausea.

From Buch's observations: Questions about CBD in the context of digestion account for approximately 18% of all inquiries. Most often, they concern feelings of bloating, constipation, and stress-related abdominal pain. This pattern is consistent with the characteristics of IBS and "stressed gut." CBD supplementation of 15-25 mg daily for 4-6 weeks is a typical first step recommended by dietitians working with the store's customers.

How do cannabinoids affect the skin?

The skin has its own fully functional endocannabinoid system. Keratinocytes, melanocytes, sebocytes, fibroblasts, and Langerhans cells produce anandamide and express CB1 and CB2 (PubMed, Trends in Pharmacological Sciences, 2009). Therefore, cannabinoids act topically on acne, atopic dermatitis, psoriasis, and itching. The CBD cosmetics market has grown globally to $1.7 billion in 2024 (Fortune Business Insights, 2024).

CBD reduces sebum production. A 2014 study on human sebocytes showed that CBD reduced lipogenesis by 30-50% and inhibited sebocyte proliferation (PubMed, Journal of Clinical Investigation, 2014). This explains CBD's effectiveness in acne. The mechanism is two-fold: direct reduction of sebum production and soothing of inflammation.

Atopic dermatitis responds to CBD by modulating the Th2 immune response. A 2019 study of 20 patients with atopic dermatitis showed a reduction in itching with 48% and improved skin hydration after three weeks of using a cream with 3% CBD. The sample size was small, but the trend is consistent with other studies.

Acne vulgaris and seborrheic dermatitis

Acne vulgaris results from a disruption of three mechanisms: sebum overproduction, excessive keratinization of the hair follicle, and proliferation of Cutibacterium acnes. CBD affects the first two. Additionally, CBG has documented antibacterial activity against C. acnes and MRSA in a 2020 study (ACS Infectious Diseases, 2020).

Combination creams containing CBD, CBG, and retinol or CBD, as well as salicylic acid, are beginning to appear in dermatological practices. This logical combination allows cannabinoids to reduce inflammation and sebum production, while standard ingredients target keratinization and bacteria. Aesthetic effects are typically observed after 6-12 weeks of regular use.

Psoriasis and atopic dermatitis

Psoriasis is an autoimmune disease characterized by excessive keratinocyte proliferation. CBD inhibits keratinocyte division and modulates T-cell activity. A 2019 study of 20 patients demonstrated a reduction in the PASI (Patient Severity Index) score by 35% after 12 weeks. The data are preliminary but consistent with a biological mechanism of action.

Atopic dermatitis (AD) affects approximately 10-20% children and 2-3% adults in Poland. Cannabinoids reduce itching, improve the epidermal barrier, and reduce inflammation. In small studies, symptom improvement is observed in 40-70% patients after 3-8 weeks of topical CBD 2-5% application.

What are the proven medical uses of cannabinoids?

Four cannabinoid preparations are registered as drugs in the US and EU. Epidiolex (CBD) since 2018 for refractory childhood epilepsy. Sativex (THC:CBD 1:1) for spasticity in MS and cancer pain. Marinol (dronabinol, synthetic THC) since 1985 for nausea and loss of appetite. Cesamet (nabilone) for nausea after chemotherapy (FDA, 2018).

Medical marijuana (high-THC cannabis flowers) has been legal by prescription in Poland since 2017. Indications include: chronic pain unresponsive to other treatments, spasticity in multiple sclerosis, nausea following chemotherapy, and loss of appetite in AIDS and cancer. Reimbursement is limited, with a monthly treatment costing between 500 and 1,500 PLN.

What do cannabinoids NOT treat? They won't cure cancer, clinical depression, schizophrenia, or heart disease. Some studies suggest supportive effects, but cannabinoids don't replace standard therapy. CBD producers in Poland are prohibited from using medical claims, in accordance with EFSA and URPL regulations.

Registrations and reimbursement in Poland

Sativex has been available in Poland since 2013 by prescription, without reimbursement, costing approximately PLN 1,200-1,600 per month. Epidiolex is available through direct import in some pediatric neurology centers. Medical marijuana (herb) has been available in pharmacies since 2019 by prescription, with limited reimbursement for selected indications.

In 2024, the Ministry of Health began consultations on broader reimbursement of medical marijuana for patients with drug-resistant epilepsy and cancer pain (Ministry of Health, 2024). The decision is expected in the second half of 2026.

CBD products available over the counter

CBD oils, capsules, gummies, and cosmetics are available over the counter in Poland. They are classified as cosmetics, collectibles, or food, depending on the manufacturer. They are not registered as medicines or dietary supplements. The Novel Food procedure has been underway since 2019.

Manufacturers are prohibited from using medical claims. They're not allowed to use phrases like "treats anxiety" or "eliminates pain." Generic phrases like "wellness support," "relaxation support," or "skin care" are acceptable. This distinguishes the consumer segment from the medical segment and protects consumers from being misled.

What is the long-term safety profile of cannabinoids?

The WHO, in a 2018 review, found CBD to be well tolerated in humans. Even high doses (up to 1,500 mg per day) do not cause significant adverse effects (WHO Expert Committee on Drug Dependence, 2018). CBD is non-addictive, does not cause withdrawal symptoms, and has a low potential for abuse. The most common side effects include drowsiness, diarrhea, and dry mouth.

THC has a different profile. The addiction potential is approximately 91 TP3T in users. For comparison: alcohol 151 TP3T, nicotine 321 TP3T, and heroin 231 TP3T. Long-term THC use can lead to short-term memory impairment, decreased motivation, and anxiety. In people under 25, the risk is significantly higher due to the ongoing development of the prefrontal cortex.

Minor cannabinoids (CBG, CBN, CBC) have a preliminary safety profile similar to CBD, but long-term data are lacking. Most studies span several weeks to six months. Data beyond 12 months mainly concern CBD in the context of childhood epilepsy (Epidiolex), where patients have been using the drug chronically since 2018.

Adverse reactions in practice

Drowsiness: most common with CBD at doses above 30 mg. This disappears in most people after 1-2 weeks of regular use. Dry mouth (xerophthalmos): affects 10-20% users and resolves with good hydration. Diarrhea: usually at high doses (above 50 mg), often related to the carrier oil, not the CBD itself.

Less common side effects include increased liver enzymes (primarily at doses above 100 mg/kg in epilepsy studies), decreased appetite, and mild headaches. In Epidiolex registration studies, approximately 151 TP3T patients had elevated ALT, usually asymptomatic. This is rare in healthy adults at typical consumer doses.

Drug interactions: CYP3A4 and CYP2C9

CBD inhibits the CYP3A4 and CYP2C9 enzymes. These enzymes metabolize approximately 50% drugs on the market. The clinical impact is strongest for drugs with a narrow therapeutic index: warfarin (bleeding risk), clobazam (sedation risk), carbamazepine, cyclosporine, tacrolimus (PMC, Epilepsy Currents, 2019).

Practical recommendations: Separate CBD from medications by at least two hours. Monitor coagulation parameters if taking warfarin. Consult a pharmacist if taking multiple medications concurrently. For most medications, healthy use of CBD in doses of 20-50 mg does not cause clinically significant problems, but in the geriatric population with polypharmacy, caution is particularly warranted.

Pregnancy, breastfeeding, pediatrics

Pregnancy: There is insufficient data on the safety of cannabinoids during pregnancy. Animal models suggest an effect on fetal brain development. The WHO and FDA recommend against use during pregnancy and breastfeeding. This is an area where caution is paramount.

Children: Epidiolex is approved for use in children aged 2 years and older for drug-resistant epilepsy. Beyond these medical indications, no data are available. Prophylactic use of CBD in healthy children is not recommended and is not supported by the literature.

Seniors: This group is at the highest potential risk of drug interactions due to polypharmacy. This group also has the highest nutritional needs (joint pain, insomnia, anxiety). Consultation with a physician and pharmacist is recommended before starting supplementation.

The WHO, in a 2018 review, found CBD to be well tolerated in humans at doses up to 1,500 mg daily. CBD is not addictive and does not cause psychoactivity (WHO Expert Committee on Drug Dependence, 2018). Interactions with drugs metabolized by CYP3A4 and CYP2C9 enzymes require major clinical attention.

How to safely introduce cannabinoids into supplementation?

The "start low, go slow" principle is universal. Start with 10-20 mg of CBD daily, monitor your response for 3-7 days, and gradually increase weekly. The full effect of ECS modulation is visible after 2-4 weeks of regular use (Project CBD, 2023). This is not symptomatic treatment, but regulatory, so patience pays off.

One drop of standard 5% oil contains approximately 2.5 mg of cannabinoid. 10% oil has 5 mg per drop. The sublingual form (drops under the tongue, 60-90 seconds) gives a bioavailability of 13-19%, compared to 6-12% after a capsule (PMC, Frontiers in Pharmacology, 2020). For most people, this is the best compromise between convenience and effectiveness.

Product selection requires careful consideration. A Certificate of Analysis (COA) should be published by the manufacturer for each batch. Check for: CBD, CBG, and CBN content, terpene profile, and the absence of pesticides, heavy metals, and mycotoxins. Broad-spectrum (THC-free) is the safest choice for professional drivers and athletes on the anti-doping list.

Choosing the right form

Sublingual oils: fastest onset (15-45 minutes), highest bioavailability. Best for daily supplementation. Capsules: convenient, repeatable dosing, but slower absorption (60-120 minutes) and lower bioavailability. Edibles: similar to capsules, plus gradual release.

Cosmetics (creams, ointments, serums): local action. They don't significantly enter the bloodstream. Good for acne, psoriasis, atopic dermatitis, joint and muscle pain. They won't help with sleep or stress systemically. Vaporizable herb: fastest action (2-5 minutes), high bioavailability (approx. 30%), but shorter duration of effect (2-3 hours).

Dosing protocols for specific purposes

Evening sleep and relaxation: 20-40 mg of CBD 60 minutes before bed. Daytime stress and anxiety: 10-25 mg of CBD in the morning and afternoon. Post-workout pain and recovery: 25-50 mg of CBD orally plus topical CBD ointment. Acne and skin conditions: CBD 2-5% cream twice daily. Cognitive support: 10-20 mg of CBG in the morning.

Doses higher than 50 mg per day are rarely needed for wellness purposes. The exception is medical treatment under medical supervision (e.g., refractory epilepsy, spasticity in multiple sclerosis, cancer pain), where doses can reach 200-1,500 mg per day. This is the domain of medicine, not supplementation.

When to consult a doctor

If you are taking medications (especially warfarin, clobazam, carbamazepine, cyclosporine, and antiepileptic drugs), consultation is mandatory. Also consult your doctor if you have liver, kidney, or heart disease. Do not use if you are pregnant or breastfeeding. If you are scheduled for surgery, inform your anesthesiologist.

For healthy, drug-free adults, cannabinoids are safe at typical wellness doses (10-50 mg of CBD daily). Consultation is recommended if effects do not occur after 4-6 weeks or if disturbing symptoms appear (e.g., increased anxiety, difficulty concentrating).

Data from Bucha 2024-2026: Based on customer observations, the most common reasons for CBD supplementation failure include: too low a dose (approximately 45% cases), too short a duration of use (30%), poor product quality without a COA (15%), and lack of consultation when combining with medications (10%). The "start low, go slow" protocol for 4 weeks increases subjective effectiveness by over 60%.

The most common myths about cannabinoids and health

According to the 2023 Project CBD survey, approximately 41% of consumers have incorrect beliefs about the effects of CBD, and for THC this percentage reaches 55% (Project CBD, 2023). Myths often have a commercial origin, but some stem from the simplifications of the press and the internet. Let's organize the facts based on available research.

Myth 1: „CBD cures cancer”

False. In vitro and animal studies show anticancer properties of some cannabinoids. However, this does not translate to cancer treatment in humans. CBD may help cancer patients relieve pain, nausea, and anxiety, but it does not replace chemotherapy, radiotherapy, or immunotherapy. Manufacturers in Poland are prohibited from making such claims.

Myth 2: "The more CBD, the better"„

False. The dose-response curve for CBD is an inverted U-shaped curve. In a 2019 study on social anxiety, a 300 mg dose produced the best effect, with higher doses (600, 900 mg) producing a weaker effect. For most users, the optimal dose is 20-50 mg per day. Exceeding this dose typically provides no additional benefit and may increase side effects.

Myth 3: „CBD is as addictive as THC”

False. In 2018, the WHO confirmed that CBD is not addictive and has no abuse potential. It does not cause withdrawal symptoms upon discontinuation. THC has an addiction potential of approximately 9%, while CBD has virtually zero. This is a fundamental pharmacological difference, crucial for safety.

Myth 4: „CBD causes a positive test result for THC”

Broad spectrum (THC-free) and isolate products are false. Full spectrum products contain up to 0.31 TP3T THC, which theoretically could produce a trace signal in sensitive tests, but in practice, standard roadside and workplace tests fail to detect such low concentrations. Professional drivers and athletes should choose broad spectrum for complete safety.

Frequently Asked Questions

How do cannabinoids affect human health?

Cannabinoids modulate the endocannabinoid system (ECS), which regulates sleep, mood, pain, immunity, metabolism, and digestion. In the Medical Cannabis and Cannabinoids study (2023), 66% participants reported improved sleep after one month of CBD supplementation, and 52% reported reduced anxiety after 8 weeks. The WHO considered CBD's safety profile favorable (WHO, 2018).

Are cannabinoids safe for long-term use?

A 2018 WHO review found CBD to be well-tolerated in humans at doses up to 1,500 mg daily. The most common side effects are drowsiness, diarrhea, and dry mouth. Long-term data (beyond 12 months) are limited, so the WHO recommends further clinical trials (WHO Expert Committee on Drug Dependence, 2018).

Which body systems do cannabinoids affect?

CB1 receptors predominate in the central nervous system, while CB2 receptors predominate in the immune system. Additionally, cannabinoids affect the skeletal, metabolic, digestive, reproductive, and skin systems. ECS receptors have been found in almost every human organ (PMC, Pharmacological Reviews, 2020).

Do cannabinoids help with chronic pain?

A Cochrane review (2018) indicated that cannabinoids reduce neuropathic pain by at least 30% in approximately 39% patients, compared to 33% in the placebo group. Sativex (THC:CBD) is registered in Poland for spasticity in MS. The effects are moderate but clinically significant (Cochrane Database, 2018).

Does CBD interact with medications?

Yes. CBD inhibits the CYP3A4 and CYP2C9 enzymes, which metabolize approximately 50% drugs on the market. Warfarin, statins, antiepileptic drugs, and some antidepressants require special caution. It is recommended to separate CBD from medications by at least 2 hours and consult a doctor (PMC, 2019).

What are the proven medical uses of cannabinoids?

Epidiolex (CBD) has been approved by the FDA for the treatment of refractory childhood epilepsy since 2018. Sativex and Nabiximols are approved in the EU and Poland for spasticity in multiple sclerosis. Dronabinol is used for nausea after chemotherapy and loss of appetite in AIDS (FDA, 2018).

Summary: What is worth remembering about cannabinoids and health?

Cannabinoids are modulators of the endocannabinoid system, which regulates virtually every aspect of homeostasis in mammals. The ECS encompasses the brain, gut, skin, bones, metabolism, immunity, and gonads. This is why cannabinoids have such a wide range of potential applications, from sleep and anxiety to chronic pain, IBD, and acne.

CBD remains the most researched non-psychoactive cannabinoid. Its safety profile is confirmed by the WHO. It is FDA and EMA registered. Minor cannabinoids (CBG, CBN, CBC) are gaining popularity but require more clinical research. THC has documented medical uses but requires prescription and professional supervision due to its psychoactive effects.

Dose gradually. Start with 10-20 mg of CBD daily. Increase every 3-7 days. Expect full effects after 2-4 weeks of regular use. Choose products with COAs. Consult your doctor if you are taking medications metabolized by CYP3A4 or CYP2C9. Avoid during pregnancy, breastfeeding, and in children unless medically indicated.

Cannabinoids are not a magic pill. They are a tool for modulating a crucial biological system. Used wisely, they can be a valuable adjunct to preventative health care. Research is ongoing, and in the next decade, we can expect an even more complete picture of the possibilities and limitations of cannabinoids in medicine and wellness.

This article is for informational and educational purposes and does not constitute medical advice. Before starting to use cannabis or CBD for therapeutic purposes, consult with a doctor, especially if you are taking other medications, are pregnant, or breastfeeding.

Author: Michał Waluk, Editor of the Bucha blog
Publication date: April 23, 2026
Last update: April 23, 2026